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ABSTRACT
Introduction Currently National Institute for Health and 
Care Excellence clinical guidelines in the UK suggest 
that surgeons performing partial hip replacements 
(hemiarthroplasty) should consider using the lateral 
approach. Alternatively, a newer, modified posterior 
approach using a muscle sparing technique named ‘Save 
Piriformis and Internus, Repairing Externus’ (SPAIRE) can 
be used leaving the major muscles intact. This randomised 
controlled trial (RCT) aims to compare the SPAIRE 
approach to the standard lateral approach, to determine 
if it allows patients to mobilise better and experience 
improved function after surgery.
Methods and analysis HemiSPAIRE is a two- arm, 
assessor- blinded, definitive pragmatic RCT with nested 
pilot and qualitative studies. Two hundred and twenty- 
eight participants with displaced intracapsular fractures 
requiring hip hemiarthroplasty will be individually 
randomised 1:1 to either the SPAIRE, or control (standard 
lateral approach) surgical procedure. Outcomes will 
be assessed at postoperative day 3 (POD3) and 120 
(POD120). The primary outcome measure will be level 
of function and mobility using the Oxford Hip Score 
at POD120. Secondary outcomes include: De Morton 
Mobility Index (DEMMI), Cumulated Ambulatory Score 
and Numeric Pain Rating Scale (NPRS) at POD3; DEMMI, 
NPRS and EQ- 5D- 5L at POD120, complications, acute 
and total length of hospital stay, and mortality. Primary 
analysis will be on an intention- to- treat basis. Participant 
experiences of the impact of surgery and recovery period 
will be examined via up to 20 semi- structured telephone 
interviews.
Ethics and dissemination The protocol has been 
approved by Yorkshire and the Humber—Bradford Leeds 
Research Ethics Committee. Recruitment commenced 
in November 2019. Findings will be disseminated via 
research articles in peer- reviewed journals, presentations 
at conferences, public involvement events, patient groups 
and media releases. A summary of the trial findings will be 
shared with participants at the end of the study.
Trial registration number NCT04095611.
INTRODUCTION
Hip fractures are common in the elderly. Over 
20 000 cases of hip hemiarthroplasty (replace-
ment of the fractured femoral head) are 
performed annually in England, Wales and 
Strengths and limitations of this study
 ► Comprehensive patient and public involvement: out-
come measures were inspired by patients who said 
that mobility and speed to regaining independence 
are the most important outcomes after partial hip 
replacement surgery.
 ► Addresses the current evidence gap on the impact 
on patient mobilisation and function after surgery 
using different techniques (Save Piriformis and 
Internus, Repairing Externus vs lateral).
 ► A pragmatic multicentre study across six National 
Health Service Trusts in the South West of England 
with broad inclusion criteria to recruit a population 
that will mirror as close as possible this frail group 
of patients as reduced cognition is not an exclusion 
criterion.
 ► Due to the frail characteristics of the target popu-
lation, a relatively high dropout rate is anticipated, 
however, this has been accounted for in the sample 
size calculation.
 ► Due to COVID-19, the primary outcome measure 
was changed to a self- report measure, meaning 
some outcomes were not collected in the manner 
originally planned.
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Northern Ireland.1 Hip fracture patients endure debili-
tating loss of function, and recovery is often complex and 
challenging.2 The average total length of stay for hip frac-
ture admissions is over 21 days, representing over 4000 
National Health Service (NHS) hospital beds occupied by 
hip fracture patients at any one time.3
The National Institute for Health and Care Excellence 
(NICE) recommends replacement arthroplasty (total 
hip replacement or hemiarthroplasty) to patients with a 
displaced intracapsular hip fracture. For patients who are 
not eligible for total hip replacement, hemiarthroplasty 
should be offered.4 As a commonly performed procedure, 
it is important to consider innovative hemiarthroplasty 
techniques that may allow better and safer rehabilitation 
in this frail group of patients.
When planning a hip hemiarthroplasty, surgeons have a 
choice of surgical approaches. NICE guidelines4 currently 
recommend using a lateral rather than a conventional 
posterior approach. This advice is based on evidence 
described as being of ‘very poor quality’.4 For adequate 
exposure, the lateral approach requires division and 
subsequent repair of 50% or more of the tendon attach-
ments of the gluteus medius and minimus muscles on to 
the greater trochanter. These muscles are essential for 
normal gait. Literature quoted suggests a reduced dislo-
cation rate for the lateral approach; however, this surgery 
has the disadvantage that the relatively extensive division 
of tendon attachments required may result in reduced 
levels of function postoperatively. Recent evidence from 
a cohort of over 20 000 patients from the Norwegian 
Hip Fracture Register5 reported better patient- related 
outcome measures (pain, patient satisfaction and health- 
related quality of life) with a standard posterior approach 
compared with the lateral approach. However, the study 
also confirmed the higher dislocation rates in the conven-
tional posterior approach group. Some studies report 
dislocation in up to 10% of patients undergoing this hip 
procedure through a standard posterior approach and 
such complications can lead to potentially catastrophic 
consequences.6
To address the issue of dislocation in hip arthroplasty, 
modified surgical procedures have been attempted using 
muscle sparing techniques. In 2012, Han et al6 described 
a modified posterior approach for use in patients with 
neurological disorders requiring hip hemiarthroplasty, 
where the piriformis, gemellus superior, obturator 
internus and part of quadratus femoris muscles were left 
intact, which combined with a standard capsule repair led 
to a reduced incidence of dislocation.6
In 2016, the Hip Unit at the Royal Devon and Exeter 
NHS Foundation Trust developed a modified technique 
using a posterior approach for hip hemiarthroplasties 
applicable to all patients. This approach involves divi-
sion of only the obturator externus tendon and part of 
quadratus femoris muscle from their femoral insertions. 
These are repaired, along with the posterior capsule, 
at the end of the surgery, with strong non- absorbable 
suture (as opposed to a standard repair) through an 
enhanced trans- osseous technique onto the posterior 
aspect of the greater trochanter. This is a modification of 
the more extensive posterior repair technique developed 
by Carlton Savory, MD at The Hughston Clinic, Georgia, 
USA. The tendon insertions of piriformis, gemellus supe-
rior, obturator internus and gemellus inferior muscles 
are spared, and the extensive abductor muscle insertions 
of gluteus medius and gluteus minimus onto the greater 
trochanter are left undisturbed, minimising the poten-
tial negative impact of dividing muscles during surgery 
on postoperative recovery and mobility. This technique 
is named ‘SPAIRE’ as it allows the surgeon to ‘Save Piri-
formis and Internus, Repairing Externus’. These muscles 
have been shown to act as the main extensor and abductor 
of the flexed hip which is of significant importance 
for movements such as rising from a chair or climbing 
stairs.7 This contrasts to the standard lateral approach, 
where a significant proportion of the gluteal muscle 
insertions is divided, potentially impacting hip func-
tion. The combination of this muscle sparing approach 
with an enhanced capsule repair aims to provide suffi-
cient stability to enable patients to mobilise full- weight 
bearing, without any of the specific restrictions currently 
included in routine postoperative posterior approach 
protocols. The preservation of these muscle insertions 
may replicate or even surpass the improved patient- 
related outcome measures observed in the study by Kris-
tensen et al5 and might achieve other benefits relating 
to more complete rehabilitation, reduced hospital stay 
and diminished requirement for social service support 
on discharge, with consequent savings from the health 
and social care budget.
Review of existing evidence
A scoping review identified 13 studies that compared the 
traditional posterior approach with the lateral approach, 
including two randomised controlled trials (RCTs).8 
These evidence a trend for increased incidence of dislo-
cation using the traditional posterior approach versus 
other approaches, with the exception of one paper 
describing good results with a modified version of the 
posterior approach.9 However, this approach was only 
attempted in a small subset of the population prone to 
these fractures. Evidence with regard to other outcomes 
is inconsistent and of limited quality, with few RCTs to 
inform guidelines.8
Aims
HemiSPAIRE is an RCT which, with its focus on post-
operative function and mobility, aims to provide high 
quality evidence on the relative benefits of the SPAIRE 
surgical technique when compared with standard lateral 
technique. The findings may help to inform and update 
current guidelines.4 In doing so it aims to contribute to 
improved function, mobility and quality of life outcomes 
for hip fracture patients, many of whom are elderly and 
frail, and reduce length of hospital stays.
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Primary objective
To test whether the SPAIRE technique improves post-
operative function and mobility at 120 days following 
surgery in adults with a displaced intracapsular hip frac-
ture requiring hemiarthroplasty, compared with the stan-
dard lateral approach through conducting a definitive 
two- arm RCT.
Secondary objectives
Test whether the SPAIRE technique results in improved 
early function, mobility, pain and quality of life at 120 
days, with reduced length of hospital stay, complica-
tion rates and mortality compared with the standard 
lateral approach, through collecting secondary outcome 
measures in the trial.
Investigate how patients experience the recovery period 
and mechanisms of recovery after surgery, by conducting 
a qualitative study with a sub- sample of patients in each 
trial arm.
Engage the contribution of a patient and public involve-
ment (PPI) group to ensure the conduct and outputs of 
the study are relevant and useful to patients.
METHODS AND ANALYSIS
Trial design
This is a definitive pragmatic, multi- centre RCT in 
patients attending hospital with a displaced intracapsular 
fracture requiring hip hemiarthroplasty. Patients will be 
randomised to have their operation performed either by 
posterior approach (SPAIRE technique) or the standard 
lateral approach. Patients, ward staff and all research 
staff involved in postoperative evaluations will remain 
blinded to allocation. Outcomes will be recorded on 
the third postoperative day (POD3) and 120 days after 
surgery (POD120). These include measures of function, 
mobility, quality of life, pain, surgical complications, 
hospital length of stay, mortality, discharge destination 
and place of residence. Figure 1 shows a flow chart of the 
trial design.
Trial setting
Six acute hospitals in the South West of England are 
recruitment centres, with a minimum of two surgeons per 
site. Training has been provided by the chief investigator 
(CI) and co- applicant JT, using lectures, mentorship, 
Figure 1 Flow chart of trial design, with anticipated numbers of participants. SPAIRE, Save Piriformis and Internus, Repairing 
Externus.
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observations, videos and one- to- one sessions as necessary. 
All participating surgeons have carried out a minimum 
of five cases using the posterior approach (SPAIRE 
technique) prior to participating in the study, and are 
prepared to undertake both procedures. Each partici-
pating surgeon uses both techniques. If a surgeon is not 
in equipoise, then he/she will not participate. Trainees 
who complete training under direct supervision of the 
principal investigator (PI) at each site are eligible to 
operate under supervision and are included on the list of 
surgeon collaborators.
Participant eligibility criteria
All patients requiring hemiarthroplasty for a displaced 
intracapsular hip fracture are considered for inclu-
sion. Inclusion criteria: patients aged 60 years or older 
presenting with an intracapsular hip fracture requiring 
hip hemiarthroplasty4 who are resident in the South West 
of England. Exclusion criteria: patients who were immo-
bile (unable to walk) before hip fracture, patients not 
expected to live until POD120 due to chronic illness and 
receiving surgery for palliative care, and use of femoral 
stems not of a proven stem design, in line with recom-
mendations set by NICE clinical guideline on hip fracture 
management.4 A sizeable proportion of this population 
suffer dementia and/or temporary delirium, and are not 
excluded; cognitive ability is not part of the eligibility 
criteria.
Trial procedures
Recruitment and participant identification
When a patient attends hospital with a confirmed intra-
capsular hip fracture, they are considered for inclusion. 
If potentially eligible the study is discussed with the 
patient and/or their carer(s). Surgery usually takes place 
12 hours or more after admission or on the day after, 
providing patients with time to consider their participa-
tion. Potential participants are identified by orthopaedic 
surgeons involved in the study (co- applicants and collab-
orators) who admit patients under their care.
Consent
Identified patients interested in participating in the study 
are invited to read the participant information sheet and, 
if interested, to provide informed consent. Researchers 
will be present to encourage potential participants to ask 
questions and to ensure participants fully understand the 
purpose of the research, risks associated with the interven-
tion, obligations of participation and their right to with-
draw at any time. The main consent forms must be fully 
completed and signed before patients are accepted on to 
the study (see online supplemental material provided). 
The qualitative consent form, if applicable, must be fully 
completed and signed between baseline and POD3. If a 
patient lacks capacity and is unable to consent, potential 
participation is discussed and consent later sought with a 
person whose relationship to the patient makes them suit-
able to act as his/her legal representative, for example, 
personal or professional consultee. If possible, the study 
is discussed or communicated to the participant in a way 
appropriate to their understanding. Participants who 
lack the mental capacity to consent and do not seem in 
agreement with any part of the study, even if agreement 
has been given by another, are not included. The partic-
ipant’s general practitioner is notified by letter that his/
her patient is participating in the study.
Randomisation scheme
Randomisation is undertaken as late as practically possible. 
There is no special preparation required in theatre, and 
no difference in equipment required for either surgical 
technique. Participants will be individually randomised 
to receive the SPAIRE or lateral procedure in a 1:1 ratio. 
Concealed allocation is determined by the UKCRC regis-
tered Exeter Clinical Trials Unit (CTU) using a validated 
password- protected web- based system. Allocation is based 
on random permuted blocks of varying size, and strati-
fied by study site and by cognition level (impaired vs non- 
impaired). The surgeon is informed of allocation by the 
CTU via email through  nhs. net mail. The CI and PI at site 
are copied in.
Blinding
Patients, and research staff performing outcome assess-
ments are blinded to treatment allocation. Surgeons and 
operative team are unblinded. An unblinded coordinator 
transcribes the surgical data to the database. There is no 
difference between the SPAIRE and lateral approach tech-
niques in the following: surgical time taken, application 
of surgical dressing or postoperative care. For medico-
legal reasons, the surgical approach used in the proce-
dure is specified in the operation notes. A cover sheet is 
attached in front of the printed operation note stating 
that the patient is a participant in the trial and reminding 
the research team to avoid inadvertent unblinding to 
treatment allocation during postoperative assessments.
Trial treatments
Trial interventions
The two groups differ only in the surgical approach to 
the hemiarthroplasty. All preparation for surgery, patient 
positioning, skin incision, other aspects of surgery, 
surgical dressing and postoperative care, are the same 
according to current practice.
SPAIRE technique through the posterior approach to the hip
If randomised to this arm of the trial, the SPAIRE technique 
is performed. This involves a modified muscle- sparing 
posterior approach where insertions of piriformis, supe-
rior gemellus, obturator internus and inferior gemellus 
are spared with division of only obturator externus and 
part of quadratus femoris. The single divided tendon and 
posterior capsule are subsequently repaired with a tran-
sosseous repair to their initial position prior to closure. 
The insertions of the abductor muscles are left intact 
throughout the procedure.
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Lateral approach to the hip
If randomised to this arm of the trial, the patient is 
prepared and the operation performed in accordance 
with criteria set by the study, so as to minimise issues of 
standardisation with this approach. This means that the 
gluteus medius and minimus insertions onto the greater 
trochanter are partially divided anteriorly, leaving the 
posterior part of their insertions intact. The anterior 
capsule is divided and subsequently repaired prior to 
closure, followed by repair of the detached portion of the 
gluteal muscles.
Baseline data collection and trial outcome assessments
Prefracture (baseline) participant characteristics, 
collected on the day of surgery, include: physical status at 
time of operation, measured using the American Society 
of Anaesthesiologists’ (ASA) Physical Status Classification 
and level of cognition, determined by the surgical team, 
using the Abbreviated Mental Test. Prefracture mobility 
and quality of life measures, collected retrospectively at 
3 days after surgery, include: Oxford Hip Score (OHS) 
and EuroQol EQ- 5D- 5L.
For details of trial outcome assessments see table 1.
Qualitative research
We are conducting up to 20 semi- structured telephone 
interviews with patients (10 per arm) to examine their 
experience of the impact of surgery and recovery period, 
including factors such as pain, mobility, function, inde-
pendence and quality of life. Participants are sampled 
from across participating sites. Interviews are conducted 
at POD120, after the quantitative data are collected, to 
gather information on patient experiences over the 
4 months after their surgery. Written consent to take 
part in a telephone interview is included within the main 
trial consent form and confirmed verbally with patients 
when contacted for interview. Patients who lack capacity 
to consent are not contacted. The interview schedule is 
designed with advice from the patient and public involve-
ment group, and two physiotherapists. Data will be anal-
ysed using thematic analysis,10 with NVivo V.12.11 The 
analysis will employ a combined deductive and induc-
tive approach, and be underpinned by a critical realist 
perspective. We will triangulate the qualitative findings 
Table 1 Trial outcome assessments, with time- points
Objective Outcome assessment Tests conducted at
Primary
  Assess postoperative function and 
mobility
The Oxford Hip Score (OHS) 120 days after surgery
Secondary
  
  Assess postoperative function and 
early mobility
The De Morton Mobility Index (DEMMI) 
test
3 and 120 days after surgery
The Cumulated Ambulation Score (CAS) 3 days after surgery
  Assess pain Numeric Pain Rating Scale (NPRS) 3 and 120 days after surgery
  Measure quality of life EuroQol EQ- 5D- 5L 120 days after surgery
  Assess analgesia medication use Analgesia medication use recorded from 
patient notes
3 and 120 days after surgery
  Measure hospital stay Acute and total length of hospital stay At time of discharge from acute and 
overallhospital stay
  Assess any negative consequences of 
care
  
Adverse events (AE) and serious adverse 
events (SAEs), defined as any negative 
consequence of care resulting in 
unintended injury or illness
Continually throughout study 
participation, on average 120 days
  Assess complication rates Specific hip- related complications: 
dislocation, nerve injury, periprosthetic 
fracture, infection within 120 days of 
operation and need for re- operation (with 
reasons)
Within 120 days after surgery, recording 
the date of complication
  Record discharge destination The percentage of participants who are 
discharged to their prefracture place of 
residence
At time of discharge from hospital 
admission
  Return to place of residence Place of residence. The percentage of 
participants returning to their prefracture 
place of residence
At 120 days after surgery
  Estimate survival Mortality within 120 days of the operation Within 120 days after surgery, recording 
the date of death
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with quantitative findings on mobility, function and 
quality of life.
Patient safety and reporting
This trial follows Sponsor (Royal Devon and Exeter NHS 
Trust) standard operating procedures (SOPs) on safety 
reporting. Serious Adverse Events (SAEs) within this study 
are defined as any untoward medical occurrence that:
 ► Results in death.
 ► Is life- threatening.
 ► Requires inpatient hospitalisation or prolongation of 
existing hospitalisation.
 ► Results in persistent or significant disability/
incapacity.
 ► Other ‘important medical events’ may also be consid-
ered serious if they jeopardise the participant or 
require an intervention to prevent one of the above 
consequences.
All SAEs will be reported to Exeter CTU and the local 
site Research and Development team within 24 hours of 
the PI being aware of the event. Exeter CTU follows up all 
SAEs. An SAE occurring to a participant is reported to the 
research ethics committee (REC) where, in the opinion 
of the CI the event was ‘related’ (resulted from admin-
istration of any of the research procedures) and ‘unex-
pected’ in relation to those procedures, within 15 working 
days of the CI becoming aware of the event. Any adverse 
event that does not fit the definition of serious above is 
recorded and reported in 6 monthly safety reports to the 
Independent Data Monitoring Committee/Trial Steering 
Committee (IDMC/TSC).
Sample size
The primary outcome is the OHS measured at POD120. 
This gives a score between 0 and 48.12 13 The minimal clin-
ically important difference for OHS when comparing two 
groups has been estimated to be 5 points, with an SD of 
9 points.14 If we conservatively use an SD of 10 (ie, an 
effect size of 0.5), with 90% power, based on a t- test of 
two independent means at the 5% level of significance, 
we require 85 patients per trial arm, that is, a total of 170. 
Allowing for 25% drop- out, the total recruitment target 
is 228 (114 in each arm). On average, each participating 
site is expected to recruit around 38 patients in total, or 
around two to three patients per month, over 18 months.
Monitoring recruitment and follow-up: internal pilot phase
Each site is expected to recruit two to three participants 
per month, but is allowed to recruit more participants 
if they are able to. The total target number recruited at 
6 months is 72 participants. If the total number of partici-
pants at 6 months is 60 or more, the study will continue as 
planned. If the total number of participants at 6 months 
is less than 30, the trial will be stopped. If the number is 
between 30 and 60 participants, we will review procedures 
to see what improvements might be made, and discuss 
progress with the IDMC/TSC and the funder. Follow- up 
rates will also be reviewed at 6 months and if below what 
has been predicted (ie, 75%) we will review procedures 
and see what improvements might be made. If recruit-
ment is progressing as expected, but follow- up rates are 
not as expected at 10 months the IDMC/TSC will be 
asked to decide if the trial should continue.
Statistical analysis
The primary analyses are pre- specified and a statistical 
analysis plan will be drafted and agreed by the IDMC/
TSC and signed off by the independent statistician on 
the IDMC/TSC, prior to analyses. The study will be 
reported in accordance with the principles of Consoli-
dated Standards of Reporting Trials guidelines.15 There 
are no planned interim analyses. Primary analyses will 
be conducted on an intention- to- treat basis, blinded to 
group allocation.
The primary outcome, OHS at POD120, will be 
compared between study arms using linear regression, 
adjusting for site, cognitive impairment and prefrac-
ture characteristics (age, gender, place of residence, 
comorbidities (ASA grouped into categories: 1 or 2, 
3, 4+)). Continuous secondary outcomes (De Morton 
Mobility Index (DEMMI),16 Cumulative Ambulatory 
Score (CAS) and Numeric Pain Rating Scale (NPRS) 
at POD3; DEMMI, EQ- 5D- 5L, NPRS at POD120; acute 
and total length of stay) will be compared between 
study arms using linear regression, using the same 
adjustment variables. Results will be presented as 
means and SD in the two study arms and estimated 
mean differences with 95% CIs and p values. As we 
expect length of stay to be skewed, we will check the 
validity of the CIs for that outcome using bootstrap 
methods. Frequencies of death and surgical compli-
cations (by type) within 120 days follow- up will be 
presented, in the two study arms. If there is no clear 
evidence of non- proportional hazards, Cox regres-
sion will be used to analyse time to death, and time 
to complication. Discharge destination (ie, whether 
the same as prefracture place of residence), place of 
residence at 120 days (whether the same as prefrac-
ture place of residence) will be compared between 
study arms using logistic regression. For each of these 
outcomes, the number of events will be checked when 
considering adjustment factors to be included in the 
analyses.
Unadjusted analyses of the primary outcome and 
secondary outcomes will also be run.
Analysis of safety outcomes (including operative compli-
cations) will be based on the per- protocol population as 
well as on an intention- to- treat basis.
Data management and confidentiality
Data collection tools and source document identification
The data collection tool for this study is paper Case Report 
Forms (CRFs). Data are entered directly onto the CRFs 
and considered source documents. The CRF consists of 
standardised outcome measures (listed in table 1).
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Data handling and record keeping
The recruitment sites store all original signed informed 
consent forms and copies of the CRF pages. Information 
on these documents is transcribed at site to a trial data-
base. The CTU Trial Manager checks the trial database 
for data completeness and liaises with sites regarding any 
data queries.
Access to data
Direct access is granted to authorised representatives 
from the Sponsor, host institution and the regulatory 
authorities to permit trial- related monitoring, audits and 
inspections in line with participant consent.
Data protection and patient confidentiality
The trial ID is used to identify data collected on CRFs 
and stored on the CTU database. Access to the CTU 
database is password protected and limited to those 
individuals necessary for quality control, audit and 
analyses. The Sponsor acts as the data controller for 
this study and will archive identifiable information 
for up to 5 years after the study has finished. Non- 
identifiable information will be kept in an open access 
archive managed by Exeter University indefinitely.
Archiving
Archiving is authorised by the Sponsor following 
submission of the end of trial report. The Sponsor 
is responsible for archiving the essential documents. 
Exeter CTU is responsible for archiving the trial data-
base. All essential documents will be archived for 
5 years after completion of trial. Destruction of essen-
tial documents will require authorisation from the 
Sponsor.
Monitoring, audit and inspection
A Trial Monitoring Plan has been developed and 
agreed by the Trial Management Group (TMG), 
IDMC/TSC (for charter contact lead author) and CI 
based on the trial risk assessment. Monitoring is being 
conducted by the CTU Trial Manager both remotely 
using the trial database and also with in person visits 
to sites. The CTU Trial Manager monitors participant 
enrolment, consent, eligibility and allocation to trial 
groups; adherence to trial interventions and policies 
to protect participants, including reporting of harm 
and completeness, accuracy and timeliness of data 
collection. Site staff are expected to assist the Trial 
Manager when requests for information are made or 
when an in person site visit is arranged.
Patient and public involvement
The premise and the primary outcome of this trial 
was informed by discussions with patients about key 
outcomes for a separate project. We continue to inte-
grate the involvement of patients in this work, organ-
ised by patient co- applicant AA and PPI facilitator 
EC. To date patients/carers with experience of hip 
fractures have helped develop the study design, plain 
English summary, patient facing documents and the 
qualitative interview schedule; they will also be closely 




The protocol has been approved by the Yorkshire 
and the Humber—Bradford Leeds Research Ethics 
Committee (REC Reference: IRAS 258327). The trial 
is conducted in accordance with the study protocol, 
the principles of the Declaration of Helsinki, Inter-
national Conference on Harmonisation of Good 
Clinical Practice and the Medicines for Human Use 
(Clinical Trials) Regulations, 2004.17 Also in accor-
dance with the UK Policy Framework for Health and 
Social Care Research18 the Mental Capacity Act 200519 
and the Data Protection Act 2018.20 The trial has been 
adopted by the National Institute for Health Research 
(NIHR) Clinical Research Network and has relevant 
local NHS research approvals. The trial is sponsored 
by Royal Devon and Exeter NHS Trust, and managed 
by the UKCRC- registered Exeter CTU.
Amendments
Sponsor SOPs are being followed for amendments. The 
decision to make an amendment is made by the TMG 
with Sponsor approval. The Sponsor decides whether an 
amendment is substantial or non- substantial. The Exeter 
CTU Trial Manager submits amendments to the REC, 
records approvals and communicates approved amend-
ments to sites. Amendment history will be tracked and 
recorded in the Trial Master File maintained by Exeter 
CTU.
Dissemination and impact activities
Trial progress is reported at TMG and IDMC/TSC meet-
ings. We will follow established practice in our institution 
in disseminating the results of the HemiSPAIRE trial 
using the widest range possible of peer reviewed scientific 
journals, professional publications and national academic 
meetings. We will present at national and international 
conferences. If proven to be superior, the SPAIRE tech-
nique is likely to continue at recruiting sites and also 
adopted in other centres around the UK. Results will 
be incorporated into our clinical training programmes 
and we will make recommendations to regulatory bodies 
such as NICE. At the end of the trial, we will seek input 
from our PPI representatives to help disseminate a lay 
summary of the findings to study participants. Results will 
be disseminated via public involvement events, patient 
groups, networks and media releases.
Author affiliations
1Clinical Trials Unit, University of Exeter Medical School, Exeter, UK
2NIHR Applied Research Collaboration South West Peninsula (PenARC), University of 
Exeter Medical School, Exeter, UK
3Physiotherapy, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK









pen: first published as 10.1136/bm




8 Price A, et al. BMJ Open 2021;11:e045652. doi:10.1136/bmjopen-2020-045652
Open access 
4Research, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK
5NIHR Applied Research Collaboration South West Peninsula (PenARC) patient 
engagement group, University of Exeter Medical School, Exeter, UK
6Psychology Applied to Health (PAtH) Group, Institute of Health Research, University 
of Exeter Medical School, Exeter, UK
7Research Design Service, Royal Devon and Exeter NHS Foundation Trust, Exeter, 
UK
8Exeter Hip Unit, Princess Elizabeth Orthopaedic Centre, Royal Devon and Exeter 
NHS Foundation Trust, Exeter, UK
Twitter Sarah Morgan- Trimmer @SarahMTrimmer
Acknowledgements We would like to thank all those who have contributed to this 
study, including; the patients and carers who have been involved in the conception 
and planning of this research; colleagues for their advice and support. Also, the 
PIs, surgeon collaborators and research teams across the NHS Trust sites that have 
been involved in this study: Royal Devon and Exeter, Royal Cornwall Hospitals, 
Northern Devon Healthcare, Somerset, Yeovil Hospital and Weston Area Health.
Contributors The research idea was inspired by hip hemiarthroplasty patients. All 
co- applicants and external advisors actively contributed to the study design. SR, 
SB and JC developed the protocol. AP drafted the protocol ready for publication, 
manages the trial, and wrote amendments for ethics submission. JC leads the 
trial. RW is responsible for cross- site training on outcome measures and EG is lead 
nurse for the lead site. SB is the trial statistician. AA leads on patient and public 
involvement (PPI) representation. EC provides PPI expertise. JT provides surgical 
research expertise. RP reviewed the manuscript: he has been an RfPB- funded 
trial CI and has statistical skills, design and ethics committee experience. SM- T 
provides qualitative research expertise, supported by EC. SR provides senior trial 
management expertise, supported by AP as trial manager. All authors commented 
on the protocol and the manuscript.
Funding This study is funded by the National Institute for Health Research (NIHR) 
Research for Patient Benefit (PB- PG-0817-20039). The views expressed are 
those of the author(s) and not necessarily those of the NIHR or the Department 
of Health and Social Care. SB and EC are supported by the National Institute for 
Health Research Applied Research Collaboration South West Peninsula. The views 
expressed in this publication are those of the authors and not necessarily those of 
the National Institute for Health Research or the Department of Health and Social 
Care.
Competing interests AP, SB, EG, JT, AA, RW, RP, SM- T and EC have nothing to 
disclose. SR reports grants from NIHR RFPB, during the conduct of the study. JC 
reports grants from NIHR, during the conduct of the study.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Anna Price http:// orcid. org/ 0000- 0001- 9147- 1876
Susan Ball http:// orcid. org/ 0000- 0002- 9937- 4832
Sarah Morgan- Trimmer http:// orcid. org/ 0000- 0001- 5226- 9595
REFERENCES
 1 RCP. Royal College of physicians. National hip fracture database 
annual report 2017 London, 2016. https://www. nhfd. co. uk/ 
2017report
 2 McGilton KS, Davis AM, Naglie G, et al. Evaluation of patient- 
centered rehabilitation model targeting older persons with a hip 
fracture, including those with cognitive impairment. BMC Geriatr 
2013;13:136.
 3 RCP. Royal College of physicians. National hip fracture database 
annual report 2016 London, 2016. Available: https://www. rcplondon. 
ac. uk/ projects/ outputs/ national- hip- fracture- database- annual- report- 
2016
 4 NICE. Hip fracture: the management of hip fracture in adults 
(CG124), 2011. Available: https://www. nice. org. uk/ guidance/ cg124
 5 Kristensen TB, Vinje T, Havelin LI. Posterior approach compared to 
direct lateral approach resulted in better patient- reported outcome 
after hemiarthroplasty for femoral neck fracture: 20,908 patients from 
the Norwegian hip fracture register. Acta Orthop 2017;88:29–34.
 6 Han S- K, Kim Y- S, Kang S- H. Treatment of femoral neck fractures 
with bipolar hemiarthroplasty using a modified minimally invasive 
posterior approach in patients with neurological disorders. 
Orthopedics 2012;35:e635–40.
 7 Vaarbakken K, Steen H, Samuelsen G, et al. Lengths of the external 
hip rotators in mobilized cadavers indicate the quadriceps coxa as 
a primary abductor and extensor of the flexed hip. Clin Biomech 
2014;29:794–802.
 8 Fullam J, Theodosi PG, Charity J, et al. A scoping review comparing 
two common surgical approaches to the hip for hemiarthroplasty. 
BMC Surg 2019;19:32.
 9 Parker MJ. Lateral versus posterior approach for insertion of 
hemiarthroplasties for hip fractures: a randomised trial of 216 
patients. Injury 2015;46:1023–7.
 10 Braun V, Clarke V. Using thematic analysis in psychology. Qual Res 
Psychol 2006;3:77–101.
 11 QSR International Pty Ltd. NVivo qualitative data analysis software, 
version 12, 2018.
 12 Dawson J, Fitzpatrick R, Carr A, et al. Questionnaire on the 
perceptions of patients about total hip replacement. J Bone Joint 
Surg Br 1996;78:185–90.
 13 Murray DW, Fitzpatrick R, Rogers K, et al. The use of the Oxford hip 
and knee scores. J Bone Joint Surg Br 2007;89:1010–4.
 14 Beard DJ, Harris K, Dawson J, et al. Meaningful changes for the 
Oxford hip and knee scores after joint replacement surgery. J Clin 
Epidemiol 2015;68:73–9.
 15 Schulz KF, Altman DG, Moher D, et al. Consort 2010 statement: 
updated guidelines for reporting parallel group randomised trials. 
BMC Med 2010;8:18.
 16 de Morton NA, Harding KE, Taylor NF, et al. Validity of the de Morton 
mobility index (DEMMI) for measuring the mobility of patients with 
hip fracture during rehabilitation. Disabil Rehabil 2013;35:325–33.
 17 Statutory instrument no 1031. Statutory instrument no 1031. 
medicines for human use (clinical trials) regulations 2004. London: 
The Stationery Office, 2004.
 18 NHS Health Research Authority. UK policy framework for health and 
social care research. London: Health Research Authority, 2017.
 19 Statutory Instrument. Mental capacity act 2005. London: The 
Stationery Office, 2005.
 20 Statutory Instrument. Data protection act 2018. London: The 
Stationery Office, 2018.









pen: first published as 10.1136/bm
jopen-2020-045652 on 8 June 2021. D
ow
nloaded from
 
